Meta Subscription Push Could Add Billions in Recurring Revenue, Says Rosenblatt 
Australia Sues 3M for Over A$2 Billion Over PFAS Firefighting Foam Contamination 
SQM Q1 Profit More Than Doubles as Lithium Prices Surge 
Xiaomi Shares Drop After Weak Q1 Earnings Amid Rising Smartphone Costs 
DOJ Investigates Group Linked to Reid Hoffman Over E. Jean Carroll Lawsuit Funding 
CTOC Goes Live on Bitget Wallet Trading, Expanding Global Access to AI-Powered Healthcare Data Ecosystem 
Snowflake Stock Soars 30% After Q1 Earnings Beat and Major AWS AI Partnership 
US Quantum Stocks Surge After $2 Billion Government Investment 
Elon Musk Explores Possible Tesla-SpaceX Merger Amid Growing AI Investments 
JPMorgan Sees Biotech Sector at Turning Point, Upgrades Top Pharma Stocks 
European EV Sales Surge in April 2026 as Tesla and Chinese Automakers Gain Ground 
Mega IPOs Like SpaceX and OpenAI Could Reshape S&P 500 and Nasdaq 100 Portfolios in 2026 
Kentucky School District Secures $27 Million in Social Media Addiction Lawsuit Settlements 
Costco Q3 Fiscal 2026 Earnings Beat Expectations as Sales and E-Commerce Surge 
SK Hynix Joins $1 Trillion Club as AI Chip Demand Fuels Stock Surge 
MongoDB Q1 FY2027 Earnings Beat Expectations, Raises Full-Year Outlook 
Dell Raises 2027 Revenue Forecast as AI Server Demand Drives Record Quarterly Results 
India’s Sun Pharmaceutical Industries (NSE: SUN) has announced a major acquisition, agreeing to purchase U.S.-based Organon & Co (NYSE: OGN) in an all-cash deal valued at approximately $11.75 billion. The move marks a significant step in Sun Pharma’s strategy to expand its global presence and strengthen its position in key pharmaceutical segments, including women’s health, branded generics, innovative medicines, and biosimilars.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash. This acquisition is expected to significantly enhance Sun Pharma’s product portfolio by adding more than 70 established and innovative medicines across women’s health and general therapeutic areas. Organon’s strong footprint in over 140 international markets will also provide Sun Pharma with broader geographic reach and improved market penetration.
Organon, which was spun off from Merck (NYSE: MRK) in 2021, has demonstrated solid financial performance. The company reported revenue of $6.2 billion and adjusted EBITDA of $1.9 billion for 2025, making it an attractive target for expansion-focused pharmaceutical companies. By integrating Organon’s assets, Sun Pharma aims to accelerate growth and diversify its revenue streams.
Following the completion of the deal, the combined entity is projected to generate pro forma revenue of around $12.4 billion. This would position Sun Pharma among the top 25 global pharmaceutical companies. Additionally, the acquisition is expected to establish Sun Pharma as a top-three player in the global women’s health market and the seventh-largest company in the biosimilars segment.
Sun Pharma plans to finance the transaction through a combination of internal cash reserves and committed bank financing. The deal has already received approval from both companies’ boards and is expected to close in early 2027, pending regulatory clearances and shareholder approvals. This strategic acquisition underscores Sun Pharma’s ambition to become a leading global pharmaceutical powerhouse while expanding its influence in high-growth therapeutic areas.
